Met Gene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cabozantinib Effective in Treating Metastatic Kidney Cancer
by Angela Mohan on 
February 15, 2021 at 3:21 PM
Cabozantinib was found most effective in treating patients with metastatic papillary kidney cancer, as per results of a SWOG Cancer Research Network trial.
These findings will be presented at ASCO s virtual 2021 Genitourinary Cancers Symposium 2021. The findings will be simultaneously published in
The Lancet.
There are currently no effective treatments for metastatic papillary kidney cancer, or metastatic pRCC, a rare subtype of kidney cancer. One study of 38 patients found that the average survival rate was eight months after diagnosis.
Sumanta Pal, MD, clinical professor of medical oncology at City of Hope, a comprehensive cancer center, and an investigator at SWOG, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), said there is hope for metastati ....

Counselingkidney Diseasecancer Factscancertattoos , Sumanta Pal , John Wright , Development Agreement , National Clinical Trials Network , Investigational Drug Branch , National Cancer Institute , Benjamin Maughan At Huntsman Cancer Institute , National Institutes Of Health , University Of Utah , Cancer Therapy Evaluation Program , Exelixis Inc , Pfizer Inc , Cancer Research Network , Research Network , Cancers Symposium , National Institutes , Benjamin Maughan , Huntsman Cancer Institute , Cooperative Research , Drug Branch , Kidney Cancer , Targeted Drugs , Met Gene , சுமந்தா நண்பா , ஜான் ரைட் ,